Background Pancreatic cancer is an aggressive type of cancer with very little treatment options that are mostly disappointing especially in the advanced stages of disease, were the cancer has spread…
Background - Glioblastoma and BRAF BRAFV600E mutations are rarely encountered in adult glioblastoma with an incidence ranging from less than 1% to 8%. But young adults, i.e. 17 to 35…
Background Interim analysis of the phase 3 LUNAR trial led to a recommendation to reduce the number of lung cancer patients required. This recommendation is based on the strongly positive…
Background A study published in the prestigious JAMA Oncology (The Journal of the American Medical Association) confirmed an association between maximal resection of contrast-enhanced tumor and survival in patients with…
Background The FDA granted fast track designation to Onivyde injection for the treatment of patients with Small Cell Lung Cancer, SCLC, who progressed following a first-line platinum-based regimen. The fast…
Background Women with advanced ovarian cancer have limited treatment options in the standard of care and therefore they have much better chances and hope in fighting their disease with new…
A Compassionate Drug is a new drug. So, first of all one needs to know that a Compassionate Drug is a new drug. The newest there is. This is a…
Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the time until the disease recurred,…
Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option for patients with metastatic colorectal…
Background Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable and effective therapies. About the…